Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.

ABSTRACT:

Background

Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy.

Patients and methods

This prospective study involved 53 mCRC patients receiving standard first-line chemotherapy. Both ctDNA and CEA were assessed in plasma collected before treatment, 3 days after treatment and before cycle 2. Computed tomography (CT) scans were carried out at baseline and 8-10 weeks and were centrally assessed using RECIST v1.1 criteria. Tumors were sequenced using a panel of 15 genes frequently mutated in mCRC to identify candidate mutations for ctDNA analysis. For each patient, one tumor mutation was selected to asses

SUBMITTER: Tie J 

PROVIDER: S-EPMC4511218 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature